Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi

Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi

Abstract Background In this phase 2 randomised placebo-controlled clinical trial in patients with COVID-19, we hypothesised that blocking mineralocorticoid receptors using a combination of dexamethasone to suppress cortisol secretion and spironolactone is safe and may reduce illness severity. Method...

Full description

Bibliographic Details
Main Authors: Bharti Wadhwa, Vikas Malhotra, Sukhyanti Kerai, Farah Husain, Nalini Bala Pandey, Kirti N. Saxena, Vinay Singh, Tom M. Quinn, Feng Li, Erin Gaughan, Manu Shankar-Hari, Bethany Mills, Jean Antonelli, Annya Bruce, Keith Finlayson, Anne Moore, Kevin Dhaliwal, Christopher Edwards
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Infectious Diseases
Subjects:
COVID-19
Spironolactone
Infectious diseases
Respiratory medicine
Online Access:https://doi.org/10.1186/s12879-023-08286-w

Internet

https://doi.org/10.1186/s12879-023-08286-w

Similar Items